Quick Takeaways
- SPRY - ARS Pharmaceuticals, Inc. has 29 insiders with reported activity on this page.
- Net insider value flow over the last year: -$21,306,510.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 29 Insiders of ARS Pharmaceuticals, Inc.
- Symbol
- SPRY on Nasdaq
- Location
- San Diego, CA
What Changed
- Buy value: ; sell value: $21,306,510.
- Net share flow: -1,343,826.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$21,306,510.
Buys
$0
Shares: 0
Insiders: 0
Sells
$21,306,510
Shares: 1,343,826
Insiders: 9
Net
-$21,306,510
Shares: -1,343,826
Insiders: -9
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 188,208 | $0 | $1,666,197 | -$1,666,197 |
| 6-9 | 0 | 112,500 | $0 | $1,615,600 | -$1,615,600 |
| 9-12 | 0 | 1,043,118 | $0 | $18,024,713 | -$18,024,713 |
ARS Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sarina Tanimoto | CHIEF MEDICAL OFFICER, 10%+ Owner | $203,017,758 | -$703,755 | -0.35% | Mixed | 02 Jan 2026 |
| Richard E. Lowenthal | PRESIDENT AND CEO, Director, 10%+ Owner | $202,790,460 | -$724,345 | -0.36% | Mixed | 02 Jan 2026 |
| James E. Flynn | 10%+ Owner | $180,437,416 | -$13,663,151 | -7% | Filing P/S | 27 Jun 2025 |
| Pratik Shah | Director | $44,969,267 | Mixed | 12 Nov 2025 | ||
| Laura Shawver | Director | $2,587,466 | Filing P/S | 25 Jun 2025 | ||
| Alexander A. Fitzpatrick | Chief Legal Officer | $1,263,238 | -$1,451,513 | -53% | Filing P/S | 02 Jan 2026 |
| Kathleen D. Scott | Chief Financial Officer | $302,017 | -$892,665 | -75% | Mixed | 02 Jan 2026 |
| Jonathan Piazza | Chief Financial Officer | $261,878 | Mixed | 02 May 2022 | ||
| Valerie Odegard | President and CSO | $233,180 | Mixed | 02 May 2022 | ||
| Naomi Hunder | Chief Medical Officer | $205,897 | Mixed | 02 May 2022 | ||
| Jeffrey C. Pepe | Interim CEO and GC | $197,938 | Mixed | 02 Sep 2022 | ||
| Eric Karas | Chief Commercial Officer | $175,259 | -$494,861 | -74% | Filing P/S | 02 Jan 2026 |
| Russ Hawkinson | Sr. Vice President of Finance | $140,921 | Mixed | 02 May 2022 | ||
| Brian Dorsey | Chief Operating Officer | $93,936 | -$190,050 | -67% | Filing P/S | 02 Jan 2026 |
| Justin Chakma | Chief Business Officer | $0 | -$1,476,147 | -100% | Mixed | 02 Jan 2026 |
| Brent L. Saunders | Director | $0 | -$1,710,024 | -100% | Mixed | 25 Jun 2025 |
| Peter A. Thompson | Director | $0 | Mixed | 25 Jun 2025 | ||
| ORBIMED ADVISORS LLC | Director | $0 | Mixed | 26 Aug 2024 | ||
| Jonathan S. Leff | Director | Mixed | 08 Nov 2022 | |||
| Rajeev Dadoo | Director | Mixed | 25 Jun 2025 | |||
| Michael Kelly | Director | Mixed | 25 Jun 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | Director, 10%+ Owner | Mixed | 25 Jun 2025 | |||
| Saqib Islam | Director | Mixed | 25 Jun 2025 | |||
| Phillip M. Schneider | Director | Mixed | 25 Jun 2025 | |||
| Jonathan D. Root | Director | Mixed | 10 Jun 2022 | |||
| Maria Koehler | Director | Mixed | 10 Jun 2022 | |||
| Andrew Kenneth William Powell | Director | Mixed | 10 Jun 2022 | |||
| Vickie L. Capps | Director | Mixed | 10 Jun 2022 | |||
| Robert Hershberg | Director | Mixed | 10 Jun 2022 |
Top shareholders of ARS Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Sarina Tanimoto |
3/4/5
|
CHIEF MEDICAL OFFICER, 10%+ Owner |
—
mixed-class rows
|
12,468,141
mixed-class rows
|
$203,017,758 | -$703,755 | 02 Jan 2026 | |
| Richard E. Lowenthal |
3/4/5
|
PRESIDENT AND CEO, Director, 10%+ Owner |
—
mixed-class rows
|
12,418,141
mixed-class rows
|
$202,790,460 | -$724,345 | 02 Jan 2026 | |
| James E. Flynn |
3/4/5
13D/G
|
10%+ Owner · Deerfield Management Company, L.P. |
7.8%
from 13D/G
|
9,774,508
|
$180,437,416 | -$13,663,151 | 27 Jun 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
13D/G
3/4/5
|
Company · Director, 10%+ Owner |
11%
from 13D/G
|
10,860,977
|
$126,530,382 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
8.4%
|
8,288,510
|
$96,561,142 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
7.6%
|
7,503,812
|
$87,419,410 | — | 31 Dec 2025 | |
| Rubric Capital Management LP |
13F
13D/G
|
Company |
6.3%
from 13D/G
|
6,200,000
|
$72,230,000 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
5,085,317
|
$59,243,944 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
6%
|
5,916,030
|
$48,748,087 | +$4,322,622 | 27 Mar 2026 | |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
|
Company |
4.1%
|
4,012,903
|
$46,750,320 | — | 31 Dec 2025 | |
| Pratik Shah |
3/4/5
|
Director |
—
mixed-class rows
|
4,504,554
mixed-class rows
|
$44,969,267 | — | 12 Nov 2025 | |
| Aberdeen Group plc |
13F
|
Company |
3.6%
|
3,556,049
|
$41,427,971 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.6%
|
3,509,174
|
$40,881,877 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.3%
|
3,223,581
|
$37,554,719 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.6%
|
2,543,097
|
$29,627,082 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
2.2%
|
2,210,866
|
$25,756,589 | — | 31 Dec 2025 | |
| Tyro Capital Management LLC |
13F
|
Company |
2%
|
1,994,852
|
$23,240,025 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2%
|
1,954,472
|
$22,769,599 | — | 31 Dec 2025 | |
| Casdin Capital, LLC |
13F
|
Company |
1.6%
|
1,600,000
|
$18,640,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,552,870
|
$18,093,898 | — | 31 Dec 2025 | |
| Southpoint Capital Advisors LP |
13F
|
Company |
1.5%
|
1,500,000
|
$17,475,000 | — | 31 Dec 2025 | |
| Janney Montgomery Scott LLC |
13F
|
Company |
1.3%
|
1,287,832
|
$15,003,000 | — | 31 Dec 2025 | |
| BAMCO INC /NY/ |
13F
|
Company |
1.3%
|
1,268,532
|
$14,778,398 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.82%
|
812,036
|
$9,460,219 | — | 31 Dec 2025 | |
| FIL Ltd |
13F
|
Company |
0.82%
|
810,073
|
$9,437,350 | — | 31 Dec 2025 | |
| LEVIN CAPITAL STRATEGIES, L.P. |
13F
|
Company |
0.76%
|
747,506
|
$8,708,445 | — | 31 Dec 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
0.67%
|
660,703
|
$7,697,190 | — | 31 Dec 2025 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.65%
|
643,407
|
$7,495,692 | — | 31 Dec 2025 | |
| CenterBook Partners LP |
13F
|
Company |
0.58%
|
568,361
|
$6,621,406 | — | 31 Dec 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.57%
|
566,056
|
$6,594,551 | — | 31 Dec 2025 | |
| GENERAL AMERICAN INVESTORS CO INC |
13F
|
Company |
0.57%
|
559,959
|
$6,523,522 | — | 31 Dec 2025 | |
| Third Point LLC |
13F
|
Company |
0.56%
|
556,237
|
$6,480,161 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.56%
|
552,364
|
$6,435,049 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.56%
|
550,932
|
$6,418,358 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.53%
|
521,009
|
$6,069,756 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.49%
|
482,084
|
$5,616,279 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.46%
|
455,766
|
$5,309,674 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.42%
|
418,883
|
$4,879,987 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.42%
|
417,090
|
$4,859,098 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.4%
|
398,959
|
$4,647,872 | — | 31 Dec 2025 | |
| Lisanti Capital Growth, LLC |
13F
|
Company |
0.4%
|
396,509
|
$4,619,330 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.37%
|
369,569
|
$4,305,479 | — | 31 Dec 2025 | |
| Empire Life Investments Inc. |
13F
|
Company |
0.36%
|
352,602
|
$4,107,813 | — | 31 Dec 2025 | |
| INVESTMENT MANAGEMENT ASSOCIATES INC /ADV |
13F
|
Company |
0.32%
|
311,503
|
$3,629,010 | — | 31 Dec 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.31%
|
304,445
|
$3,546,785 | — | 31 Dec 2025 | |
| Creek Drive Management Group LLC |
13F
|
Company |
0.3%
|
295,863
|
$3,446,804 | — | 31 Dec 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.26%
|
251,593
|
$2,931,058 | — | 31 Dec 2025 | |
| Laura Shawver |
3/4/5
|
Director |
—
mixed-class rows
|
240,346
mixed-class rows
|
$2,587,466 | — | 25 Jun 2025 | |
| Steward Partners Investment Advisory, LLC |
13F
|
Company |
0.22%
|
216,296
|
$2,519,848 | — | 31 Dec 2025 | |
| ROYCE & ASSOCIATES LP |
13F
|
Company |
0.21%
|
207,051
|
$2,412,144 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for ARS Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kathleen D. Scott | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Eric Karas | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Alexander A. Fitzpatrick | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Brian Dorsey | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Justin Chakma | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Sarina Tanimoto | SPRY | Stock Option (right to buy) | Award | 875,000 | 875,000 | 02 Jan 2026 | By Spouse | |||
| Sarina Tanimoto | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Richard E. Lowenthal | SPRY | Stock Option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | By Spouse | |||
| Richard E. Lowenthal | SPRY | Stock option (right to buy) | Award | 875,000 | 875,000 | 02 Jan 2026 | Direct | |||
| Brian Dorsey | SPRY | Common Stock | Sale | -66.9% | $190,050 | $8.71 | -21,828 | 10,789 | 13 Nov 2025 | Direct |
| Brian Dorsey | SPRY | Common Stock | Options Exercise | 202.3% | 21,828 | 32,617 | 13 Nov 2025 | Direct | ||
| Brian Dorsey | SPRY | Stock Option (Right to Buy) | Options Exercise | -100% | -21,828 | 0 | 13 Nov 2025 | Direct | ||
| Justin Chakma | SPRY | Common Stock | Sale | -100% | $1,476,147 | $8.87 | -166,380 | 0 | 12 Nov 2025 | Direct |
| Justin Chakma | SPRY | Common Stock | Options Exercise | 22% | 30,000 | 166,380 | 12 Nov 2025 | Direct | ||
| Justin Chakma | SPRY | Stock Option (Right to Buy) | Options Exercise | -25.2% | -30,000 | 89,047 | 12 Nov 2025 | Direct | ||
| Pratik Shah | SPRY | Common Stock | Gift | -7.25% | -350,000 | 4,474,554 | 12 Nov 2025 | By The Pratik Shah Living Trust dated June 15, 2011 | ||
| Richard E. Lowenthal | SPRY | Common Stock | Sale | -4.01% | $724,345 | $14.49 | -50,000 | 1,196,494 | 21 Aug 2025 | By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 |
| Kathleen D. Scott | SPRY | Common Stock | Sale | -55.4% | $187,500 | $15.00 | -12,500 | 10,042 | 21 Aug 2025 | Direct |
| Kathleen D. Scott | SPRY | Common Stock | Options Exercise | 124.5% | 12,500 | 22,542 | 21 Aug 2025 | Direct | ||
| Kathleen D. Scott | SPRY | Stock Option (Right to Buy) | Options Exercise | -1.66% | -12,500 | 739,830 | 21 Aug 2025 | Direct | ||
| Sarina Tanimoto | SPRY | Common Stock | Sale | -2.93% | $530,626 | $14.09 | -37,656 | 1,247,447 | 20 Aug 2025 | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 |
| Sarina Tanimoto | SPRY | Common Stock | Sale | -0.95% | $173,130 | $14.03 | -12,344 | 1,285,103 | 19 Aug 2025 | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 |
| Eric Karas | SPRY | Common Stock | Sale | -59.2% | $254,860 | $16.99 | -15,000 | 10,315 | 01 Jul 2025 | Direct |
| Eric Karas | SPRY | Common Stock | Options Exercise | 145.4% | 15,000 | 25,315 | 01 Jul 2025 | Direct | ||
| Eric Karas | SPRY | Stock Option (Right to Buy) | Options Exercise | -2.68% | -15,000 | 544,588 | 01 Jul 2025 | Direct | ||
| James E. Flynn | SPRY | Class A Common Stock | Sale | -7.04% | $6,831,566 | $18.46 | -370,074 | 4,887,254 | 27 Jun 2025 | Through Deerfield Private Design Fund IV, L.P. |
| James E. Flynn | SPRY | Class A Common Stock | Sale | -7.04% | $6,831,584 | $18.46 | -370,075 | 4,887,254 | 27 Jun 2025 | Through Deerfield Private Design Fund III, L.P. |
| Ra Capital Management, L.P. | SPRY | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | See Footnotes | |||
| Rajeev Dadoo | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Pratik Shah | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Michael Kelly | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Saqib Islam | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Peter A. Thompson | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Brent L. Saunders | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Phillip M. Schneider | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Laura Shawver | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Eric Karas | SPRY | Common Stock | Sale | -66.1% | $240,000 | $16.00 | -15,000 | 7,696 | 18 Jun 2025 | Direct |
| Eric Karas | SPRY | Common Stock | Options Exercise | 194.9% | 15,000 | 22,696 | 18 Jun 2025 | Direct | ||
| Eric Karas | SPRY | Stock Option (Right to Buy) | Options Exercise | -2.61% | -15,000 | 559,588 | 18 Jun 2025 | Direct | ||
| Alexander A. Fitzpatrick | SPRY | Common Stock | Sale | -53.5% | $1,451,513 | $14.10 | -102,969 | 89,613 | 20 May 2025 | Direct |
| Alexander A. Fitzpatrick | SPRY | Common Stock | Options Exercise | 108% | 100,000 | 192,582 | 20 May 2025 | Direct | ||
| Alexander A. Fitzpatrick | SPRY | Stock Option (Right to Buy) | Options Exercise | -33.3% | -100,000 | 200,000 | 20 May 2025 | Direct | ||
| Brent L. Saunders | SPRY | Common Stock | Sale | -100% | $1,710,024 | $14.25 | -120,000 | 0 | 20 May 2025 | Direct |
| Brent L. Saunders | SPRY | Common Stock | Options Exercise | 120,000 | 120,000 | 20 May 2025 | Direct | |||
| Brent L. Saunders | SPRY | Stock Option (Right to Buy) | Options Exercise | -20.3% | -120,000 | 470,950 | 20 May 2025 | Direct | ||
| Kathleen D. Scott | SPRY | Common Stock | Sale | -87.1% | $705,165 | $14.10 | -50,000 | 7,424 | 20 May 2025 | Direct |
| Kathleen D. Scott | SPRY | Common Stock | Options Exercise | 673.5% | 50,000 | 57,424 | 20 May 2025 | Direct | ||
| Kathleen D. Scott | SPRY | Stock Option (Right to Buy) | Options Exercise | -6.23% | -50,000 | 752,330 | 20 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.